The FDA approved a supplemental application for Tagrisso (osimertinib) on April 18, 2018. The FDA record classifies the application as an efficacy supplement, but the information provided does not identify a new indication or include clinical outcome measurements.
Background
The event concerned osimertinib, also known by the brand name Tagrisso. The supplied FDA record identifies the application as a supplemental filing and labels its review class “Efficacy.” It names AstraZeneca as the sponsor. The record provided for this article does not describe the drug’s mechanism, the condition addressed by the supplement, or any prior approvals, so those details cannot be established from this source information alone.
What this means
The event confirms that the FDA approved an efficacy-related supplemental application for Tagrisso. However, the event data do not state what specific evidence supported the decision, which patient population or indication the supplement concerned, or whether the approval changed the prescribing information. No trial design, comparator, outcome measurements, statistical analyses, or safety findings are included in the supplied record. Accordingly, this notice alone does not support conclusions about the size of any treatment benefit or how the drug performed relative to another therapy.
For clinicians, researchers, and patient advocates, the key distinction is between confirmation of a supplemental approval and details of the evidence behind it: the record supports the former, but does not provide the latter. Readers seeking the indication-specific regulatory context should consult the FDA application record and associated documents, where available.
Source
Source: U.S. Food and Drug Administration (FDA), Drug Approval Package/application record for NDA 208065, supplement S-8, dated April 18, 2018. Available at accessdata.fda.gov.